The trademark application Qfitlia was filed by Genzyme Corporation, a U.S. corporation (the "Applicant"). The application was published for oppositions on October 10, 2022, and it was registered by office on January 17, 2023 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system
Pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases
Pharmaceutical preparations for the treatment of rare blood disorders, pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections
Pharmaceutical preparations for the treatment of lysosomal storage diseases.